BioPharma Dive April 22, 2024
The drugmaker has tapped Swedish partner BioArctic to develop a technology meant to more effectively deliver drugs into the brain.
Dive Brief:
- Eisai has agreed to a new deal with longtime Alzheimer’s disease partner BioArctic, signing up for a “research evaluation” of a preclinical drug designed to more effectively reach the brain. Announced Saturday, the agreement gives Eisai rights to license the drug, called BAN2802, after reviewing data from the collaboration.
- The drug uses a technology BioArctic calls “BrainTransporter,” which is meant to get antibody drugs past a biological gateway between the blood and brain. This blood-brain barrier often limits how drugmakers can treat diseases like Alzheimer’s and brain cancer.
- Begun in 2005, the Eisai-BioArctic partnership yielded the Food...
Today's Sponsors
Today's Sponsor